ライフサイエンスコーパス: mean survival time

1 the liver and kidney, and a 20% reduction in mean survival time.

2 ibed masses and yielded a 30% enhancement in mean survival time.

3 e-care facility was associated with a longer mean survival time.

4 rejected when transplanted into BALB/c mice (mean survival time: 10+/-0.8 days), normal C57BL/6 mice

5 ificantly prolonged in TLR4(-/-) recipients (mean survival time=10.6 and 14.3 days, respectively).

6 fully MHC-mismatched DBA/2 skin allografts (mean survival time, 12 days; n = 6) compared with the wi

7 transplants was more rapid than skin grafts (mean survival time, 12.9 vs. 26.6 days), and islet graft

8 me: 16.5+/-2.1 days) as well as CD8-KO mice (mean survival time: 12.8+/-1.3 days).

9 n = 8) as compared with wild-type controls (mean survival time 13 +/- 4, n = 7).

10 ype and markedly slower disease progression (mean survival time 14 years).

11 e showed significantly (P < 0.005) shortened mean survival time (16.2 +/- 5.3 months) compared to the

12 l time: 10+/-0.8 days), normal C57BL/6 mice (mean survival time: 16.5+/-2.1 days) as well as CD8-KO m

13 grafts were vigorously rejected by DKO mice (mean survival time 17 +/- 7, n = 8) as compared with wil

14 acute rejection of class I-disparate hearts (mean survival time, 19+/-7.21 vs. 38+/-8.19; P=0.025) bu

15 , >120 days), but not in CD8-deficient mice (mean survival time, 20 days).

16 sion who underwent resection of cancer had a mean survival time 25.5 months shorter than that of pati

17 ival of the kidney capsule islet xenografts (mean survival time = 26.5 +/- 7.8 days vs. 15.2 +/- 5.3

18 red to mice that received irradiation alone (mean survival time, 31 days; P=0.001).

19 who received chemotherapy alone (restricted mean survival time 34.5 months [95% CI 32.0-37.0] with s

20 6) recipients survived significantly longer (mean survival time, 38 +/- 8 days) compared with those t

21 efit of bevacizumab was recorded (restricted mean survival time 44.6 months [95% CI 43.2-45.9] in the

22 diated (600 rads), naive C57BL/6 recipients (mean survival time = 48.9 +/- 17.1 days), and three of t

23 n unimmunized cyclosporine-treated controls (mean survival time = 5.5 +/-1.7 vs. 54.7 +/-3.8 days, P

24 raft rejection compared with untreated mice (mean survival time: 54 vs. 8 days, P < 0.0001).

25 RCCs, and all grew progressively but slowly (mean survival times, 57 to >100 days) in vivo after intr

26 100 days, n=2) and rejection of third-party (mean survival time: 7.5+/-0.5 days, n=2) hearts.

27 f CsA (1.0 mg/kg/day) alone was ineffective (mean survival time=7.0+/-0.7 vs. 6.4+/-0.6 days in treat

28 n = 6) compared with the wild-type controls (mean survival time, 8 days; n = 7).

29 grafts were rejected by C57Bl/6 recipients (mean survival time=8.2 and 9.3 days, respectively), graf

30 Mean survival time among animals treated with saline or

31 Mean survival time among hemoadsorption-treated animals

32 te liver failure significantly prolonged the mean survival time and resolved the liver injury when co

33 Withdrawal significantly decreased the mean survival time and significantly increased the Salmo

34 to oral infection, as assessed by survival, mean survival time, and colony culture.

35 evidenced by increased mortality, shortened mean survival time, and increased bacterial load in the

36 rds, so we used the difference in restricted mean survival time as the primary estimate of effect.

37 whiB3 mutant strain had significantly longer mean survival times as compared with mice challenged wit

38 ed paclitaxel benefits in terms of increased mean survival time, as well as median survival time.

39 Compared with immediate initiation, the mean survival time at 7 years with a strategy of initiat

40 teins that are clinically diverse, producing mean survival times between 2 and 12 years (postdiagnosi

41 accination with YpkA significantly prolonged mean survival time but did not increase overall survival

42 r, in non-high-risk patients, the restricted mean survival time did not differ significantly between

43 higher survival rate (75% versus 62.5%) and mean survival time during the first 21 days postchalleng

44 Mean survival time for grafts incubated in F(ab')2 anti-

45 d the simulation reproduces the experimental mean survival times for all four sites with activation e

46 Likewise, mean survival times for B6 skin grafts placed on C.B6-(n

47 The mean survival times for the treated and control groups w

48 Also, sunitinib reduced mean survival times from 12 to 6 days in virus-infected

49 l of Balb/c KTx in naive C57BL/6 recipients (mean survival time >100 days vs. 52 days in controls; P<

50 lantation induced indefinite graft survival (mean survival time >140.3+/-12.3 vs. 12.7+/-0.7 control,

51 en rats were treated with FK506 monotherapy (mean survival time >60 days, n=4).

52 in allograft survival in CD4-deficient mice (mean survival time, >120 days), but not in CD8-deficient

53 st treatment in wild-type mice increased the mean survival time in response to CLP.

54 Mean survival time in the fully MHC-mismatched skin graf

55 Estimated mean survival time in the Kaplan-Meier analysis was 147

56 Mean survival time is extended from 5-7.5 weeks for cont

57 -term survival of Lewis pancreas xenografts (mean survival time (MST) >90 days).

58 Untreated control rats had a mean survival time (MST) +/- SE of 27 +/- 1 day, and irr

59 controls, 0.5 mg/kg SRL per day extended the mean survival time (MST) from 6.4+/-0.5 days to 12.3+/-3

60 ivo, 20 mg/kg 17359 prolonged survivals to a mean survival time (MST) of 18.3+/-2.6 days (P<0.001) in

61 In the ACI to Lewis combination, the mean survival time (MST) of the untreated group was 5.2

62 e incidence as wild-type control mice, their mean survival time (MST) was significantly longer than t

63 SL model demonstrated significantly improved mean survival time (MST) with single fraction whole-brai

64 sis, The incidence of graft rejection, graft mean survival time (MST), and alloimmune responses, and

65 In comparison to untreated recipients (mean survival time (MST): 5.3 +/- 0.5 days), anti-CD134L

66 ng renal allograft acceptance: the BMT/renal mean survival time (MST, 76 days) was not significantly

67 n a long-term survival of kidney allografts (mean survival time [MST] > 100.0 days, n=5).

68 heart graft rejection both in the B10-->C3H (mean survival time [MST] 7.8+/-0.2 days; control MST 10.

69 n rapid fashion either LEW heart allografts (mean survival time [MST] = 4.2+/-0.4 days vs. 5.6+/-0.5

70 nsplants of islets from BALB/c into C57BL/6 (mean survival time [MST]: 16.5 vs. 12.0 days; P = 0.004)

71 l of hamster liver xenografts in Lewis rats (mean survival time [MST]=10.5 days, n=6, and MST=9.0 day

72 The mean survival times (MSTs) of RG2 glioma bearing rats we

73 rafts in Lewis (LEW; RT1l) recipients from a mean survival time of 10.6 +/- 1.9 days in untreated con

74 loss of contractility, and ecchymosis and a mean survival time of 12.5 +/- 6.4 min.

75 tely rejected C57BL/10 islet allografts at a mean survival time of 13.8 +/- 2.7 days (n=5).

76 allograft survival (>200 days) compared to a mean survival time of 15.0+/-2.3 days in controls treate

77 reas xenografts were acutely rejected with a mean survival time of 15.3 days in B cell-deficient mice

78 4 days, whereas tumor-bearing controls had a mean survival time of 16 +/- 2 days.

79 The six Linplant implant animals had a mean survival time of 164 days (range, 1-264 days), a "l

80 largement, and severe kidney failure, with a mean survival time of 2 months.

81 RL(lpr) mice had prolonged viability, with a mean survival time of 33.0 wk compared with 22.6 wk in c

82 antation of tumor (1 x 10(5) cells) showed a mean survival time of 35 +/- 4 days, whereas tumor-beari

83 ontrast, tacrolimus + donor BM resulted in a mean survival time of 42 days (P<0.01 compared with tacr

84 ed with the control regimen (no DBM) with an mean survival time of 53 days (P=0.022).

85 ed on exogenous protamine zinc insulin had a mean survival time of 53 days (range, 10-217), a "last e

86 nated mice challenged with yeast cells had a mean survival time of 56 days, compared with <13 days fo

87 nts with none of the adverse genotypes had a mean survival time of 62.1 months, and those with one, t

88 he grafts in this model were rejected with a mean survival time of 7+/-1 days and showed extensive ev

89 rejected Lewis (RT1l) kidney allografts at a mean survival time of 8.5+/-1.1 days.

90 ents acutely rejected kidney allografts at a mean survival time of 8.8 +/- 0.75 d.

91 istar-Furth (WF; RT1u) heart allografts at a mean survival time of 8.9+/-1.0 days.

92 d to 56 days, 8.0 mg/kg/q.o.d BQR produced a mean survival time of 83.8 +/0 33.8 days (P < 0.001), wi

93 reater prolongation of graft survival with a mean survival time of 88 days compared with the control

94 ly prolonged Lewis cardiac allografts from a mean survival time of 9.8+/-0.7 days in controls to 19.8

95 (Emu) develop B-cell lymphoma and exhibit a mean survival time of approximately 6 months.

96 The mean survival time of BALB/c islet allografts transplant

97 icrovessel density as well as with decreased mean survival time of HCC patients.

98 une response that significantly improved the mean survival time of mice bearing established lung meta

99 onger tumor growth suppression and increased mean survival time of the mice compared with the treatme

100 ghly correlated with the previously reported mean survival times of animals treated with the same age

101 Kidney CFU and mean survival times of infected mice pretreated with MAb

102 pared with control groups, with </=29.2 days mean survival time (P < 0.001).

103 by the difference (and ratio) of restricted mean survival times (RMST) in oncology randomized trials

104 P < 0.001, test for difference in restricted mean survival time [RMST]), but no differences were obse

105 Despite reducing FV3 loads and extending the mean survival time, rXlIFN treatments failed to prevent

106 Mean survival time (+/-SEM) in animals treated with MMF

107 Mean survival time (+/- standard error of mean) in anima

108 had a significantly higher survival rate and mean survival time than mice immunized with only LVS Del

109 death and of death or AIDS-defining illness, mean survival time, the proportion of individuals in nee

110 transplantation prolonged cardiac allograft mean survival time to >120 days compared with untreated

111 transplantation prolonged cardiac allograft mean survival time to 25.7+/-0.9 days compared with untr

112 plantation was able to extend the Pd grafts' mean survival time to 32 months for fourteen 4 Pd grafts

113 f SRL with 0.5 mg/kg/day FTY720 extended the mean survival time to 34.4+/-8.8 days (CI=0.28).

114 10-year area under the curve; ie, restricted mean survival time) to emulate a randomized clinical tri

115 significantly protected, as reflected by the mean survival time versus control grafts (27+/-20 days [

116 The mean survival time was 118 months in low Met expression

117 The mean survival time was 14.2 months (range, 2.1-33.1 mont

118 nts with tumors that responded to treatment, mean survival time was 15 months (range, 4.5-33.1 months

119 The mean survival time was 74.4 days (SEM 6.39 days) in sali

120 The mean survival time was 8 years; however, 5 patients died

121 Finally, mean survival time was significantly longer (720 vs. 381

122 Mean survival times were 6.9 years for the continuation

123 Mean survival time, which was 51 mins in the control gro